Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegafur. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegafur SCHEMBL8537231 | 1.00 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL7698456 | 1.00 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4553 | 1.00 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4155129 | 0.98 | LMNA (0.97) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL22320166 | 0.98 | LMNA (0.97) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28304686 | 0.97 | LMNA (0.94) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28156468 | 0.97 | LMNA (0.94) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28851751 | 0.96 | LMNA (0.92) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10940658 | 0.95 | LMNA (0.91) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL1276356 | 0.90 | LMNA (0.81) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 55523 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260141690-A1 | LAYER-WISE KNOWLEDGE DISTILLATION FOR VISION LANGUAGE MODELS | NVIDIA CORP (US) | 2026-05-21 | — | — | US | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122028934-A | Combination of CLDN18_2 antibody and chemotherapeutic drug and application thereof | 江苏奥赛康生物医药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122011207-A | CAR-T cell over-expressing H2A.Z as well as preparation method and application thereof | 中国科学院微生物研究所 | 2026-05-12 | — | — | CN | claimed |
| CN-122006800-A | Cu@TS-1 molecular sieve catalyst and preparation method and application thereof | 石河子大学 | 2026-05-12 | — | — | CN | claimed |
| EP-3978473-B1 | COMPOUND CONTAINING AN INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF | BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4720132-A1 | COMBINATION THERAPIES INVOLVING CLAUDIN 18.2 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-0227593-A1 | Use of chelating agents | THE HOSPITAL FOR SICK CHILDREN (CA) | 1987-07-01 | — | — | EP | claimed |
| EP-0224885-A1 | Antitumor composition. | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1987-06-10 | — | — | EP | claimed |
| US-4650801-A | CYTOSINE TO INHIBIT DECOMPOSITION | TAIHO PHARMACEUTICAL COMPANY, LTD. (JP) | 1987-03-17 | — | — | US | claimed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | claimed |
| US-4507301-A | Anti-cancer composition for delivering 5-fluorouracil | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-03-26 | — | — | US | claimed |
| US-4328229-A | Anti-cancer composition for delivering 5-fluorouracil to cancer tissues | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1982-05-04 | — | — | US | claimed |
| US-4256885-A | 5-FLUOROURACIL AND 2,3-DIHYDROFURAN, ACID CATALYSTS | MITSUI TOATSU KAGAKU KABUSHIKI KAISHA (JP) | 1981-03-17 | — | — | US | claimed |
| US-4249006-A | Method of producing 5-fluorouracil derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-02-03 | — | — | US | claimed |
| US-3960864-A | Method of synthesizing 1-(tetrahydro-2-furanyl)-5-fluorouracil | THE UNIVERSITY OF UTAH (US) | 1976-06-01 | — | — | US | claimed |
| US-3948897-A | Synthesis of 1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) via direct fluorination | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH, EDUCATION AND WELFARE (US) | 1976-04-06 | — | — | US | claimed |